ZNTL | Zentalis Pharmaceuticals
Quick infos Headquarters: United States Trade prices Volume: Market Cap: 1.65B Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: No Dividends Next ER: March 2, 2023 After Market Closes
Company Profile Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer.
Earnings History Date EPS / Forecast Revenue / Forecast August 9, 2023 May 10, 2023 -1.07 / -1.02- / -March 1, 2023 -0.87 / -1.06- / -November 9, 2022 -0.96 / -1.22- / -August 9, 2022 -1.34 / -1.18- / -view more
Historical Data Date Price Open High Low Vol Change ER Mar 23, 2022 48.61 49.79 52.20
48.50
275.93K -4.2% Mar 22, 2022 50.74 49.50 51.85
49.20
324.60K 3.66% Mar 21, 2022 48.95 49.99 50.52
47.91
431.67K -2.68% Mar 18, 2022 50.30 48.04 50.70
48.04
1.34M 5.61% Mar 17, 2022 47.63 43.12 47.81
43.12
419.69K 9.57% Mar 16, 2022 43.47 43.65 44.49
42.02
567.66K 1.64% Mar 15, 2022 42.77 42.22 43.48
41.01
408.39K 2.86% Mar 14, 2022 41.58 43.97 44.91
40.80
521.58K -5.78% Mar 11, 2022 44.13 47.07 48.85
43.92
330.24K -5.6% Mar 10, 2022 46.75 46.71 48.71
45.72
364.87K -3.11% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2014 Employees:110 News
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely finance.yahoo.com Mar 4, 2023 10:01 am
Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated finance.yahoo.com Mar 4, 2023 7:00 am
Zentera Therapeutics Announces Closing of $75 Million Series B Financing finance.yahoo.com Mar 4, 2023 7:00 am Zentalis Pharmaceuticals gets new operations chief seekingalpha.com Feb 13, 2023 9:08 pm Zentalis Pharmaceuticals GAAP EPS of -$0.96 beats by $0.25 seekingalpha.com Nov 9, 2022 9:44 pm Zai Lab appoints Zentalis' exec as chief scientific officer seekingalpha.com Nov 8, 2022 9:28 pm
Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma finance.yahoo.com Mar 4, 2023 7:00 am
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer finance.yahoo.com Mar 4, 2023 7:00 am
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates finance.yahoo.com Mar 1, 2023 7:00 am
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Feb 1, 2023 5:00 pm
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely finance.yahoo.com Jan 17, 2023 9:18 am
Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect? finance.yahoo.com Dec 8, 2022 9:55 am
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates finance.yahoo.com Nov 9, 2022 7:00 am
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Nov 1, 2022 5:38 pm Pfizer, Zentalis plan to start phase 1/2 trial of ZN-c3 for colorectal cancer seekingalpha.com Oct 24, 2022 8:34 pm
Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy finance.yahoo.com Oct 17, 2022 7:00 am Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer seekingalpha.com Sep 28, 2022 4:10 am
Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer finance.yahoo.com Sep 27, 2022 4:01 pm Zentalis Pharmaceuticals has a new chief medical officer seekingalpha.com Sep 19, 2022 7:14 pm
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors finance.yahoo.com Sep 12, 2022 7:00 am This company doesn't provide a dividend.
Talk about Zentalis Pharmaceuticals below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.